Early backer of breakthrough,
founder-led longevity companies

All
age1
The Longevity Fund
The Longevity Fund

EXITED: IPO

First-in-class foundational checkpoint immunotherapies

NASDAQ: ALXO

The Longevity Fund

Discovering new medicines with ultra-throughput biochemistry and machine learning

age1

Next-generation interventions to cure neurodegeneration and delay brain aging

The Longevity Fund

Targeting pathogenic cells to treat aging and chronic diseases

The Longevity Fund

Turning stem cells into human eggs to reimagine family planning

The Longevity Fund

EXITED: IPO

Regenerative and gene therapies to restore hearing and balance

NASDAQ: DBTX

The Longevity Fund

Activation of the endogenous immune system for eliminating pathogenic cells

The Longevity Fund

AI-led drug discovery engine translating conserved pathways of disease resistance across species

The Longevity Fund

Next generation of induced proximity medicines

The Longevity Fund

Pooled in vivo platform for new therapeutics tackling complex age-related disease

The Longevity Fund

Healthspan and lifespan extension for dogs

The Longevity Fund

EXITED: IPO

Therapies for gastrointestinal and liver disease

NASDAQ: MTCR

The Longevity Fund

Platform for therapeutics targeting mTORC1

The Longevity Fund

EXITED: IPO

Novel gene editing technology to develop new class of medicines

NASDAQ: DTIL

The Longevity Fund

Therapeutics to heal the blood-brain barrier

The Longevity Fund

Redefining human capabilities with advanced medical technology

The Longevity Fund

Machine learning platform to accelerate drug discovery for aging

The Longevity Fund

EXITED: IPO

Therapeutics to slow, halt, or reverse diseases of aging

NASDAQ: UBX

Stealth

Cryopreservation technology for tissues and organs to end organ supply shortages

Stealth

Developing therapies targeting gut-organ-axes to increase healthspan

Stealth

Multiplex-editing therapies to target age-related disease

Stealth

Precision therapeutics for genetic forms of neurodegeneration